Merck won't seek U.S., EU approval of omarigliptin

Merck & Co. Inc. (NYSE:MRK) said it will not seek approval of diabetes drug omarigliptin ( MK-3102) in the U.S. or EU. The company will continue to market the once-weekly, oral dipeptidyl peptidase-4 ( DPP-4; CD26) inhibitor in Japan as Marizev.

Merck said the decision was based on "business reasons" rather than efficacy or safety concerns. The company markets once-daily DPP-4 inhibitor Januvia sitagliptin to treat Type II diabetes. ...